<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d484" origId="Levobunolol"><sentence id="DrugDDI.d484.s0" origId="s0" text="Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur."><entity id="DrugDDI.d484.s0.e0" origId="s0.p1" charOffset="9-16" type="drug" text="BETAGAN"/><entity id="DrugDDI.d484.s0.e1" origId="s0.p12" charOffset="117-124" type="drug" text="BETAGAN"/><entity id="DrugDDI.d484.s0.e2" origId="s0.p14" charOffset="129-140" type="drug" text="epinephrine"/><pair id="DrugDDI.d484.s0.p0" e1="DrugDDI.d484.s0.e0" e2="DrugDDI.d484.s0.e1" interaction="?"/><pair id="DrugDDI.d484.s0.p1" e1="DrugDDI.d484.s0.e0" e2="DrugDDI.d484.s0.e2" interaction="?"/><pair id="DrugDDI.d484.s0.p2" e1="DrugDDI.d484.s0.e1" e2="DrugDDI.d484.s0.e2" interaction="?"/></sentence><sentence id="DrugDDI.d484.s1" origId="s1" text="Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension."><entity id="DrugDDI.d484.s1.e0" origId="s1.p22" charOffset="55-67" type="drug" text="beta-blocker"/><entity id="DrugDDI.d484.s1.e1" origId="s1.p27" charOffset="130-135" type="drug" text="drugs"/><entity id="DrugDDI.d484.s1.e2" origId="s1.p28" charOffset="144-153" type="drug" text="reserpine"/><pair id="DrugDDI.d484.s1.p0" e1="DrugDDI.d484.s1.e0" e2="DrugDDI.d484.s1.e1" interaction="?"/><pair id="DrugDDI.d484.s1.p1" e1="DrugDDI.d484.s1.e0" e2="DrugDDI.d484.s1.e2" interaction="?"/><pair id="DrugDDI.d484.s1.p2" e1="DrugDDI.d484.s1.e1" e2="DrugDDI.d484.s1.e2" interaction="?"/></sentence><sentence id="DrugDDI.d484.s2" origId="s2" text="Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension."><entity id="DrugDDI.d484.s2.e0" origId="s2.p44" charOffset="19-50" type="drug" text="beta-adrenergic blocking agents"/><entity id="DrugDDI.d484.s2.e1" origId="s2.p50" charOffset="89-107" type="drug" text="calcium antagonist"/><pair id="DrugDDI.d484.s2.p0" e1="DrugDDI.d484.s2.e0" e2="DrugDDI.d484.s2.e1" interaction="?"/></sentence><sentence id="DrugDDI.d484.s3" origId="s3" text="In patients with impaired cardiac function, simultaneous use should be avoided altogether."/><sentence id="DrugDDI.d484.s4" origId="s4" text="The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects on prolonging atrioventricular conduction time."><entity id="DrugDDI.d484.s4.e0" origId="s4.p66" charOffset="23-54" type="drug" text="beta-adrenergic blocking agents"/><entity id="DrugDDI.d484.s4.e1" origId="s4.p67" charOffset="60-69" type="drug" text="digitalis"/><entity id="DrugDDI.d484.s4.e2" origId="s4.p69" charOffset="74-92" type="drug" text="calcium antagonist"/><pair id="DrugDDI.d484.s4.p0" e1="DrugDDI.d484.s4.e0" e2="DrugDDI.d484.s4.e1" interaction="?"/><pair id="DrugDDI.d484.s4.p1" e1="DrugDDI.d484.s4.e0" e2="DrugDDI.d484.s4.e2" interaction="?"/><pair id="DrugDDI.d484.s4.p2" e1="DrugDDI.d484.s4.e1" e2="DrugDDI.d484.s4.e2" interaction="?"/></sentence><sentence id="DrugDDI.d484.s5" origId="s5" text="Phenothiazine-related compounds and beta-adrenergic blocking agents may have additive hypotensite effects due to the inhibition of each other?s metabolism."><entity id="DrugDDI.d484.s5.e0" origId="s5.p74" charOffset="0-13" type="drug" text="Phenothiazine"/><entity id="DrugDDI.d484.s5.e1" origId="s5.p76" charOffset="36-67" type="drug" text="beta-adrenergic blocking agents"/><pair id="DrugDDI.d484.s5.p0" e1="DrugDDI.d484.s5.e0" e2="DrugDDI.d484.s5.e1" interaction="?"/></sentence></document>